Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$102.72 USD

102.72
7,656,647

-0.24 (-0.23%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $102.67 -0.05 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4

by Zacks Equity Research

Cryolife (CRY) revenues increase year over year across all geographies and major segments.

Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

by Zacks Equity Research

Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

by Zacks Equity Research

Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

by Zacks Equity Research

In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

Baxter's Acute Therapies Profile Strong, Competition Rife

by Zacks Equity Research

Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.

Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

Bio-Techne (TECH) sees increase in revenues across key segments.

Boston Scientific Benefits From New Buyouts & Product Launch

by Zacks Equity Research

Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.

Here's Why Investors Should Retain AmerisourceBergen Stock

by Zacks Equity Research

AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.

Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

by Zacks Equity Research

The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research

A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.

Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong

by Zacks Equity Research

Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.

Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

by Zacks Equity Research

IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.

STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates

by Zacks Equity Research

STERIS (STE) continues to gain from strength in all business segments in Q3.

Here's Why Momentum Investors Will Love Abbott (ABT)

by Zacks Equity Research

Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.

IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

IRADIMED (IRMD) reports growth across all operating segments and geographies

Here's Why You Should Buy Wright Medical (WMGI) Stock Now

by Zacks Equity Research

A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.

Top Ranked Momentum Stocks to Buy for February 11th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 11th:

Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up

by Zacks Equity Research

Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.

Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.

Here's Why You Should Invest in McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.

Here's Why You Should Hold Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.

Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid

by Zacks Equity Research

Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.

Abbott (ABT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $69.69, moving +0.93% from the previous trading session.

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research

We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.